We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
-13%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$46B
AUM Growth
-$5.82B
Cap. Flow
+$1.91B
Cap. Flow %
4.16%
Top 10 Hldgs %
16.37%
Holding
3,033
New
111
Increased
2,420
Reduced
427
Closed
53

Top Buys

Rank Stock Value
1
LIN icon
Linde
LIN
+$127M
2
CI icon
Cigna
CI
+$54M
3
CVS icon
CVS Health
CVS
+$38.8M
4
MPC icon
Marathon Petroleum
MPC
+$28.9M
5
FANG icon
Diamondback Energy
FANG
+$19M

Sector Composition

Rank Sector Weight
1 Technology 16.95%
2 Financials 15.85%
3 Healthcare 14.41%
4 Consumer Discretionary 10.13%
5 Industrials 10.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SPRO icon
2926
Spero Therapeutics
SPRO
$73.5M
$62K ﹤0.01%
+10,010
New +$81.1K
NEOS
2927
DELISTED
Neos Therapeutics, Inc
NEOS
$62K ﹤0.01%
37,442
+12,871
+52% +$36.1K
LUMO
2928
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$61K ﹤0.01%
4,487
+1,314
+41% +$23.1K
IMDZ
2929
DELISTED
Immune Design Corp.
IMDZ
$61K ﹤0.01%
46,946
+13,660
+41% +$23.7K
FCEL icon
2930
FuelCell Energy
FCEL
$1.62B
$59K ﹤0.01%
297
+82
+38% +$23.4K
MBIO icon
2931
Mustang Bio
MBIO
$4.36M
$58K ﹤0.01%
26
+8
+44% +$24.3K
KODK icon
2932
Kodak
KODK
$925M
$57K ﹤0.01%
22,496
+6,820
+44% +$20.8K
RMNI icon
2933
Rimini Street
RMNI
$462M
$57K ﹤0.01%
+11,135
New +$64.6K
ZOM
2934
DELISTED
Zomedica Corp.
ZOM
$57K ﹤0.01%
46,410
+16,750
+56% +$26.6K
ADMA icon
2935
ADMA Biologics
ADMA
$2.33B
$56K ﹤0.01%
23,279
+7,810
+50% +$38.7K
NYMX
2936
DELISTED
Nymox Pharmaceutical Corp
NYMX
$56K ﹤0.01%
42,560
+13,180
+45% +$24.1K
WIT icon
2937
Wipro
WIT
$19.7B
$54K ﹤0.01%
28,021
NMTR
2938
DELISTED
9 Meters Biopharma
NMTR
$54K ﹤0.01%
1,169
+375
+47% +$27.8K
MTEM
2939
DELISTED
Molecular Templates, Inc.
MTEM
$53K ﹤0.01%
+875
New +$61.1K
AREX
2940
DELISTED
Approach Resources Inc.
AREX
$53K ﹤0.01%
60,842
+15,640
+35% +$23.9K
IMH
2941
DELISTED
Impac Mortgage Holdings Inc.
IMH
$53K ﹤0.01%
14,041
+3,990
+40% +$19.6K
AKAO
2942
DELISTED
Achaogen Inc
AKAO
$51K ﹤0.01%
41,268
+12,383
+43% +$33.1K
ABEV icon
2943
Ambev
ABEV
$46.5B
$50K ﹤0.01%
12,779
-2,830
-18% -$12.1K
ASX icon
2944
ASE Group
ASX
$81.9B
$50K ﹤0.01%
13,323
CTIC
2945
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$49K ﹤0.01%
66,079
+20,630
+45% +$33.9K
YARW
2946
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
$48K ﹤0.01%
+3
New +$67.2K
LYG icon
2947
Lloyds Banking Group
LYG
$90B
$47K ﹤0.01%
18,357
BBGI icon
2948
Beasley Broadcasting Group
BBGI
$42.8M
$45K ﹤0.01%
+598
New +$67.4K
SNNA
2949
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
$45K ﹤0.01%
19,377
+6,702
+53% +$59.1K
FSNN
2950
DELISTED
Fusion Connect, Inc. Common Stock
FSNN
$45K ﹤0.01%
27,040
+8,650
+47% +$19.5K

Similar funds

RhumbLine Advisers's Q4 2018 Portfolio in Review

As of Q4 2018, RhumbLine Advisers held 3,033 positions worth $46B, down 11% from $51.8B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

RhumbLine Advisers deployed $1.91B of net new capital in Q4 2018, opening 111 new positions and adding to 2,420 existing holdings. Its largest new stake was Linde: 805,738 shares worth $126M.

By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 18% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Apple, an estimated $30.2M trimmed.

  • RhumbLine Advisers's largest Q4 2018 buy was Linde: 805,738 shares worth $126M.
  • RhumbLine Advisers added most to Cigna in Q4 2018, an estimated $54M increase.
  • RhumbLine Advisers's biggest Q4 2018 reduction was Apple, cutting an estimated $30.2M.
  • RhumbLine Advisers fully exited Aetna Inc in Q4 2018, selling an estimated $124M.
  • RhumbLine Advisers's ten largest holdings make up 16% of its $46B portfolio in Q4 2018.
  • RhumbLine Advisers opened 111 new positions and closed 53 in Q4 2018.
  • RhumbLine Advisers's portfolio value fell 11% quarter-over-quarter to $46B.

Based on RhumbLine Advisers's 13F filing for Q4 2018, filed 31 Jan 2019.